The current study substantiated that CTSL is a potentially carcinogenic factor for patients with HNSCC, which helps researchers better understand the increased susceptibility of HNSCC to SARS-CoV-2 infection and lays the groundwork for SARS-CoV-2 therapy. The gene discussed is CTSL; the disease is head and neck squamous cell carcinoma.